SG&A Efficiency Analysis: Comparing Viatris Inc. and Ascendis Pharma A/S

SG&A Efficiency: A Tale of Two Companies

In the competitive landscape of the pharmaceutical industry, understanding operational efficiency is crucial. This analysis compares the Selling, General, and Administrative (SG&A) expenses of Viatris Inc. and Ascendis Pharma A/S from 2014 to 2023. Over this period, Viatris Inc. consistently reported higher SG&A expenses, peaking at approximately $4.65 billion in 2023, reflecting its expansive operations. In contrast, Ascendis Pharma A/S, a smaller player, saw its SG&A expenses grow from $6.27 million in 2014 to $264 million in 2023, marking a significant increase of over 4,100%. This growth highlights Ascendis Pharma's strategic investments in scaling its operations. The data underscores the differing strategies of these companies: Viatris's focus on maintaining a broad market presence versus Ascendis's aggressive growth trajectory. Understanding these trends provides valuable insights into their operational priorities and market strategies.